USPTO Examiner LINDGREN BALTZEL MORGAN TAYLOR - Art Unit 1636

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18591645GENETICALLY MODIFIED CELL LINES FOR METABOLIC STUDIESFebruary 2024March 2025Abandon1210NoNo
18591760GENETICALLY MODIFIED CELL LINES FOR METABOLIC STUDIESFebruary 2024March 2025Abandon1210NoNo
18372823ANTIBODY-EVADING VIRUS VECTORSSeptember 2023April 2024Allow611NoNo
17984045DIRECT REPLACEMENT GENOME EDITINGNovember 2022March 2025Abandon2840YesNo
17430134METHODS AND COMPOSITIONS FOR SELECTING A CANCER TREATMENT IN A SUBJECT SUFFERING FROM CANCERAugust 2021May 2025Abandon4501NoNo
17355605TARGETED INTEGRATION OF NUCLEIC ACIDSJune 2021January 2025Abandon4321NoNo
17334345METHOD FOR DIAGNOSING DRUG ADDICTION, METHOD FOR SCREENING THERAPEUTIC AGENT FOR DRUG ADDICTION AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DRUG ADDICTIONMay 2021October 2023Allow2911YesNo
17294982ENHANCED DETECTION OF LOW-COPY-NUMBER NUCLEIC ACIDS IN AN INTEGRATED WORKFLOWMay 2021February 2025Abandon4510NoNo
17199173SPERM CELL ISOLATION AND SPERM-ASSOCIATED DNA PURIFICATIONMarch 2021February 2025Allow4841YesNo
17167991METHODS FOR CAPTURE AND ANALYSIS OF MACROMOLECULAR COMPLEXESFebruary 2021July 2024Abandon4220NoNo
16972039METHOD OF CHARACTERIZING A POLYNUCLEOTIDEDecember 2020October 2023Allow3411YesNo
17250113SUPER HLA TYPING METHOD AND KIT THEREOFNovember 2020February 2024Abandon3930NoNo
17057771EPIGENETIC METHOD TO ESTIMATE THE INTRINSIC AGE OF SKINNovember 2020July 2023Abandon3201NoNo
17058019Enzymatic Enrichment of DNA-Pore-Polymerase ComplexesNovember 2020August 2024Abandon4530NoNo
17054935VECTOR INCLUDING A TRANSLATION-IMPAIRED DIHYDROFOLATE REDUCTASE GENE CASSETTE AND UBIQUITOUSLY ACTING CHROMATIN OPENING ELEMENTNovember 2020May 2023Allow3010NoNo
17053530METHOD FOR PRODUCING HOMOZYGOUS CELLSNovember 2020June 2023Abandon3110NoNo
17053722MASSIVELY PARALLEL DISCOVERY METHODS FOR OLIGONUCLEOTIDE THERAPEUTICSNovember 2020June 2023Abandon3210NoNo
17053336QUALITY CONTROL OF LNA OLIGONUCLEOTIDE THERAPEUTICS USING MASSIVELY PARALLEL SEQUENCINGNovember 2020April 2023Abandon3001NoNo
17052624PRODUCING RECOMBINANT PROTEINS WITH REDUCED LEVELS OF HOST CELL PROTEINSNovember 2020September 2024Abandon4610NoNo
17086619COMPOSITIONS AND KITS FOR RAPID DETECTION SCREENING OF MULTIPLE ANAPLASMA SPECIES AND METHODS OF PRODUCTION AND USE THEREOFNovember 2020April 2024Abandon4121NoNo
17050052SEQUENTIAL PAIRED-END SEQUENCINGOctober 2020July 2024Abandon4501NoNo
17045090ANTIBODY-EVADING VIRUS VECTORSOctober 2020May 2024Allow4301YesNo
17039928PROGRAMMABLE NUCLEASE COMPOSITIONS AND METHODS OF USE THEREOFSeptember 2020August 2024Abandon4611NoNo
16966407GENE THERAPY FOR LIMB-GIRDLE MUSCULAR DYSTROPHY TYPE 2CJuly 2020November 2024Allow5211YesNo
16875673METHODS FOR EVALUATING LUNG CANCER STATUSMay 2020March 2024Abandon4611NoNo
16758694Secreted Reporter-Peptides for Optimizing Cell-Based Assays for Analysis on Immuno-Assay PlatformsApril 2020April 2025Allow6020NoNo
16758844NONINVASIVE MOLECULAR CLOCK FOR FETAL DEVELOPMENT PREDICTS GESTATIONAL AGE AND PRETERM DELIVERYApril 2020May 2025Allow6021NoNo
16841521SYSTEMS AND METHODS FOR RAPID DIAGNOSTIC FOR VARIOUS CANCERSApril 2020January 2024Abandon4530NoNo
16807435Rapid Display Method in Translational Synthesis of PeptideMarch 2020January 2024Allow4720YesNo
16614878SYNTHETIC METHYLOTROPHYNovember 2019March 2025Allow6030NoNo
16489634METHODS AND SYSTEMS FOR PREDICTING TREATMENT RESPONSES IN SUBJECTSAugust 2019April 2024Abandon5621NoNo
16486287GENETICALLY MODIFIED CELL LINES FOR METABOLIC STUDIESAugust 2019October 2024Abandon6011NoNo
16426374RNA BASED BIOMATERIAL FOR TISSUE ENGINEERING APPLICATIONSMay 2019October 2024Abandon6040NoNo
16387054POLYPEPTIDE EXPRESSION SYSTEMSApril 2019August 2023Allow5210NoNo
16111475TELOMERASE ENCODING DNA VACCINEAugust 2018April 2024Allow6021YesNo
15999378CANCER EPIGENETIC PROFILINGAugust 2018January 2024Abandon6021NoNo
15977565Methods for the Treatment of Corneal DystrophiesMay 2018March 2023Allow5841NoNo
15920161METHODS AND COMPOSITIONS FOR DETECTING A TARGET RNAMarch 2018July 2023Allow6070YesNo
15491125SITE-SPECIFIC DNA MODIFICATION USING A DONOR DNA REPAIR TEMPLATE HAVING TANDEM REPEAT SEQUENCESApril 2017July 2023Allow6091YesNo
14907866SELECTION VECTORS AND METHODS OF SELECTING EUKARYOTIC HOST CELLSJanuary 2016August 2023Allow6081YesYes
14846958METHODS AND COMPOSITIONS FOR ATTENUATING GENE EDITING ANTI-VIRAL TRANSFER VECTOR IMMUNE RESPONSESSeptember 2015December 2024Abandon60140YesYes

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner LINDGREN BALTZEL, MORGAN TAYLOR.

Strategic Value of Filing an Appeal

Total Appeal Filings
2
Allowed After Appeal Filing
0
(0.0%)
Not Allowed After Appeal Filing
2
(100.0%)
Filing Benefit Percentile
0.4%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner LINDGREN BALTZEL, MORGAN TAYLOR - Prosecution Strategy Guide

Executive Summary

Examiner LINDGREN BALTZEL, MORGAN TAYLOR works in Art Unit 1636 and has examined 39 patent applications in our dataset. With an allowance rate of 43.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 46 months.

Allowance Patterns

Examiner LINDGREN BALTZEL, MORGAN TAYLOR's allowance rate of 43.6% places them in the 5% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by LINDGREN BALTZEL, MORGAN TAYLOR receive 2.49 office actions before reaching final disposition. This places the examiner in the 85% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by LINDGREN BALTZEL, MORGAN TAYLOR is 46 months. This places the examiner in the 2% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +57.4% benefit to allowance rate for applications examined by LINDGREN BALTZEL, MORGAN TAYLOR. This interview benefit is in the 96% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 16.0% of applications are subsequently allowed. This success rate is in the 7% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 15.4% of cases where such amendments are filed. This entry rate is in the 10% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 40.0% are granted (fully or in part). This grant rate is in the 38% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.